Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 15/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1873673 | 0.86 | BRAF (0.49) | BRAFCYP2C9CYP2C19CYP3A4 | |
| SCHEMBL22146305 | 0.85 | SLC40A1 (0.43) | BRAF | |
| SCHEMBL9987021 | 0.80 | BRAF (0.48) | BRAFCYP2C9CYP2C19KCNK3KCNA5 | |
| SCHEMBL9986679 | 0.80 | BRAF (0.38) | BRAFCYP2C19 | |
| SCHEMBL31443423 | 0.77 | ALDH1A1 (0.40) | — | |
| SCHEMBL1882268 | 0.76 | BRAF (0.41) | BRAFCYP2C9KCNK3KCNA5 | |
| SCHEMBL1876513 | 0.75 | BRAF (0.39) | BRAFCYP2C9 | |
| SCHEMBL3076306 | 0.74 | CTNNB1 (0.44) | — | |
| SCHEMBL26089296 | 0.74 | BRAF (0.46) | BRAF | |
| SCHEMBL855793 | 0.73 | BRAF (0.54) | BRAFCYP2C9CYP2C19CYP3A4KCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2585454-A1 | HETEROARYL COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | Novartis AG (CH) | 2013-05-01 | — | — | EP | disclosed |
| US-20130096149-A1 | HETEROARYL COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-04-18 | — | — | US | disclosed |
| WO-2011161216-A1 | HETEROARYL COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096149-A1 | HETEROARYL COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | BRAF, RAF1, ARAF | BRAF 1/4885CYP2C9 1326/4885CYP2C19 1191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.